Skip to main content Accessibility help
×
Home
Hostname: page-component-559fc8cf4f-s5ss2 Total loading time: 0.248 Render date: 2021-03-01T14:25:27.271Z Has data issue: true Feature Flags: { "shouldUseShareProductTool": true, "shouldUseHypothesis": true, "isUnsiloEnabled": true, "metricsAbstractViews": false, "figures": false, "newCiteModal": false, "newCitedByModal": true }

Proteasome Inhibitor Lactacystin Induces Cholinergic Degeneration

Published online by Cambridge University Press:  02 December 2014

Hai-Yan Zhou
Affiliation:
Department of Neurology & Institute of Neurology, Ruijin Hospital affiliated to Shanghai Jiaotong University School of Medicine
Yu-Yan Tan
Affiliation:
Department of Neurology & Institute of Neurology, Ruijin Hospital affiliated to Shanghai Jiaotong University School of Medicine
Zhi-Quan Wang
Affiliation:
Institute of Health Science, Shanghai Institutes of Biological Sciences, Chinese Academy of Science & Shanghai Jiaotong University School of Medicine, Shanghai, China
Gang Wang
Affiliation:
Department of Neurology & Institute of Neurology, Ruijin Hospital affiliated to Shanghai Jiaotong University School of Medicine
Guo-Qiang Lu
Affiliation:
Department of Neurology & Institute of Neurology, Ruijin Hospital affiliated to Shanghai Jiaotong University School of Medicine
Sheng-Di Chen
Affiliation:
Department of Neurology & Institute of Neurology, Ruijin Hospital affiliated to Shanghai Jiaotong University School of Medicine Institute of Health Science, Shanghai Institutes of Biological Sciences, Chinese Academy of Science & Shanghai Jiaotong University School of Medicine, Shanghai, China
Rights & Permissions[Opens in a new window]

Abstract

Objective:

Ubiquitin proteasome system dysfunction is believed to play an important role in the development of Parkinson's disease (PD), and almost all studies till now have mainly focused on the susceptibility of dopaminergic neurons to proteasome inhibition. However, in fact, there are many other types of neurons such as cholinergic ones involved in PD. In our present study, we attempt to figure out what effect the failure of ubiquitin proteasome function would execute on cholinergic cells in culture.

Methods:

We treated cholinergic cells in culture with various doses of lactacystin. Then MTT assay was used to evaluate the cellular viability and the Annexin V-PI method was used to detect apoptosis. Both cellular soluble and insoluble polyubiquitinated proteins were detected by western blot. Furthermore, the mitochondrial membrane potential was analyzed using JC-1 and the intracellular production of reactive oxygen species (ROS) was determined using the fluorescent probe CM-H2DCFDA.

Results:

We found that low doses of lactacystin were enough to induce significant apoptotic cell death, disturb the mitochondrial membrane potential, and cause oxidative stress. We also found that the amounts of polyubiquitinated proteins dramatically increased with high doses, although the loss of cells did not increase accordingly.

Conclusions:

Our results suggest that cholinergic cells are sensitive to ubiquitin proteasome system dysfunction, which exerts its toxic effect by causing mitochondrial dysfunction and subsequent oxidative stress, not through polyubiquitinated proteins accumulation.

Type
Research Article
Copyright
Copyright © The Canadian Journal of Neurological 2010

References

1. Dawson, TM, Dawson, VL. Molecular pathways of neurodegeneration in Parkinson’s disease. Science. 2003;302(5646):81922.CrossRefGoogle ScholarPubMed
2. McNaught, KS, Olanow, CW. Proteolytic stress: a unifying concept for the etiopathogenesis of Parkinson’s disease. Ann Neurol. 2003;53 Suppl 3:S7384.CrossRefGoogle ScholarPubMed
3. Moore, DJ, West, AB, Dawson, VL, Dawson, TM. Molecular pathophysiology of Parkinson’s disease. Annu Rev Neurosci. 2005;28:5787.CrossRefGoogle ScholarPubMed
4. Polymeropoulos, MH, Lavedan, C, Leroy, E, Ide, SE, Dehejia, A, Dutra, A, et al. Mutation in the alpha-synuclein gene identified in families with Parkinson’s disease. Science. 1997;276(5321): 20457.CrossRefGoogle ScholarPubMed
5. Kitada, T, Asakawa, S, Hattori, N, Matsumine, H, Yamamura, Y, Minoshima, S, et al. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature. 1998;392(6676):6058.Google Scholar
6. Leroy, E, Boyer, R, Auburger, G, Leube, B, Ulm, G, Mezey, E, et al. The ubiquitin pathway in Parkinson’s disease. Nature. 1998;395(6701):4512.CrossRefGoogle ScholarPubMed
7. Bonifati, V, Rizzu, P, van Baren, MJ, Schaap, O, Breedveld, GJ, Krieger, E, et al. Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism. Science. 2003;299(5604):2569.CrossRefGoogle ScholarPubMed
8. McNaught, KS, Jenner, P. Proteasomal function is impaired in substantia nigra in Parkinson’s disease. Neurosci Lett. 2001;297(3):1914.CrossRefGoogle ScholarPubMed
9. McNaught, KS, Belizaire, R, Jenner, P, Olanow, CW, Isacson, O. Selective loss of 20S proteasome alpha-subunits in the substantia nigra pars compacta in Parkinson’s disease. Neurosci Lett. 2002;326(3):1558.CrossRefGoogle ScholarPubMed
10. McNaught, KS, Belizaire, R, Isacson, O, Jenner, P, Olanow, CW. Altered proteasomal function in sporadic Parkinson’s disease. Exp Neurol. 2003;179(1):3846.CrossRefGoogle ScholarPubMed
11. Fornai, F, Lenzi, P, Gesi, M, Ferrucci, M, Lazzeri, G, Busceti, CL, et al. Fine structure and biochemical mechanisms underlying nigrostriatal inclusions and cell death after proteasome inhibition. J Neurosci. 2003;23(26):895566.Google ScholarPubMed
12. McNaught, KS, Perl, DP, Brownell, AL, Olanow, CW. Systemic exposure to proteasome inhibitors causes a progressive model of Parkinson’s disease. Ann Neurol. 2004;56(1):14962.CrossRefGoogle ScholarPubMed
13. Schapira, AH, Cleeter, MW, Muddle, JR, Workman, JM, Cooper, JM, King, RH. Proteasomal inhibition causes loss of nigral tyrosine hydroxylase neurons. Ann Neurol. 2006;60(2):2535.CrossRefGoogle ScholarPubMed
14. Mathur, BN, Neely, MD, Dyllick-Brenzinger, M, Tandon, A, Deutch, AY. Systemic administration of a proteasome inhibitor does not cause nigrostriatal dopamine degeneration. Brain Res. 2007;1168:839.CrossRefGoogle Scholar
15. Landau, AM, Kouassi, E, Siegrist-Johnstone, R, Desbarats, J. Proteasome inhibitor model of Parkinson’s disease in mice is confounded by neurotoxicity of the ethanol vehicle. Mov Disord. 2007;22(3):4037.CrossRefGoogle ScholarPubMed
16. Kordower, JH, Kanaan, NM, Chu, Y, Suresh Babu, R, Stansell, J 3rd, Terpstra, BT, et al. Failure of proteasome inhibitor administration to provide a model of Parkinson’s disease in rats and monkeys. Ann Neurol. 2006;60(2):2648.CrossRefGoogle ScholarPubMed
17. Manning-Boğ, AB, Reaney, SH, Chou, VP, Johnston, LC, McCormack, AL, Johnston, J, et al. Lack of nigrostriatal pathology in a rat model of proteasome inhibition. Ann Neurol. 2006;(2):25660.CrossRefGoogle Scholar
18. Hawlitschka, A, Haas, SJ, Schmitt, O, Weiss, DG, Wree, A. Effects of systemic PSI administration on catecholaminergic cells in the brain, adrenal medulla and carotid body in Wistar rats. Brain Res. 2007;1173:13744.CrossRefGoogle ScholarPubMed
19. Braak, H, Del Tredici, K, Rub, U, de Vos, RA, Jansen Steur, EN, Braak, E. Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol Aging. 2003;24(2):197211.CrossRefGoogle ScholarPubMed
20. Ahlskog, JE. Challenging conventional wisdom: the etiologic role of dopamine oxidative stress in Parkinson’s disease. Mov Disord. 2005;20(3):27182.CrossRefGoogle ScholarPubMed
21. Zarow, C, Lyness, SA, Mortimer, JA, Chui, HC. Neuronal loss is greater in the locus coeruleus than nucleus basalis and substantia nigra in Alzheimer and Parkinson diseases. Arch Neurol. 2003;60(3):33741.CrossRefGoogle ScholarPubMed
22. Rideout, HJ, Lang-Rollin, IC, Savalle, M, Stefanis, L. Dopaminergic neurons in rat ventral midbrain cultures undergo selective apoptosis and form inclusions, but do not up-regulate iHSP70, following proteasomal inhibition. J Neurochem. 2005;93(5): 130413.CrossRefGoogle Scholar
23. Suh, J, Lee, YA, Gwag, BJ. Induction and attenuation of neuronal apoptosis by proteasome inhibitors in murine cortical cell cultures. J Neurochem. 2005;95(3):68494.CrossRefGoogle ScholarPubMed
24. Lang-Rollin, I, Vekrellis, K, Wang, Q, Rideout, HJ, Stefanis, L. Application of proteasomal inhibitors to mouse sympathetic neurons activates the intrinsic apoptotic pathway. J Neurochem. 2004;90(6):151120.CrossRefGoogle ScholarPubMed
25. Qiu, JH, Asai, A, Chi, S, Saito, N, Hamada, H, Kirino, T. Proteasome inhibitors induce cytochrome c-caspase-3-like proteasemediated apoptosis in cultured cortical neurons. J Neurosci. 2000;20(1):25965.Google ScholarPubMed
26. Sullivan, PG, Dragicevic, NB, Deng, JH, Bai, Y, Dimayuga, E, Ding, Q, et al. Proteasome inhibition alters neural mitochondrial homeostasis and mitochondria turnover. J Biol Chem. 2004;279(20):20699707.CrossRefGoogle ScholarPubMed
27. Wagenknecht, B, Hermisson, M, Groskurth, P, Liston, P, Krammer, PH, Weller, M. Proteasome inhibitor-induced apoptosis of glioma cells involves the processing of multiple caspases and cytochrome c release. J Neurochem. 2000;75(6):228897.CrossRefGoogle ScholarPubMed
28. Goldbaum, O, Vollmer, G, Richter-Landsberg, C. Proteasome inhibition by MG-132 induces apoptotic cell death and mitochondrial dysfunction in cultured rat brain oligodendrocytes but not in astrocytes. Glia. 2006;53(8):891901.CrossRefGoogle ScholarPubMed
29. Halliwell, B. Hypothesis: proteasomal dysfunction: a primary event in neurodegeneration that leads to nitrative and oxidative stress and subsequent cell death. Ann N Y Acad Sci. 2002;962:18294.CrossRefGoogle Scholar
30. Kikuchi, S, Shinpo, K, Tsuji, S, Takeuchi, M, Yamagishi, S, Makita, Z, et al. Effect of proteasome inhibitor on cultured mesencephalic dopaminergic neurons. Brain Res. 2003;964(2):22836.CrossRefGoogle ScholarPubMed
31. Mytilineou, C, McNaught, KS, Shashidharan, P, Yabut, J, Baptiste, RJ, Parnandi, A, et al. Inhibition of proteasome activity sensitizes dopamine neurons to protein alterations and oxidative stress. J Neural Transm. 2004;111(10-11):123751.CrossRefGoogle ScholarPubMed
32. Lev, N, Melamed, E, Offen, D. Proteasomal inhibition hypersensitizes differentiated neuroblastoma cells to oxidative damage. Neurosci Lett. 2006;399(1-2):2732.CrossRefGoogle ScholarPubMed
33. Yamamoto, N, Sawada, H, Izumi, Y, Kume, T, Katsuki, H, Shimohama, S, et al. Proteasome inhibition induces glutathione synthesis and protects cells from oxidative stress: relevance to Parkinson disease. J Biol Chem. 2007;282(7):436472.CrossRefGoogle ScholarPubMed
34. Hung, CC, Davison, EJ, Robinson, PA, Ardley, HC. The aggravating role of the ubiquitin-proteasome system in neurodegenerative disease. Biochem Soc Trans. 2006;34(Pt 5):7435.CrossRefGoogle ScholarPubMed
35. Ardley, HC, Hung, CC, Robinson, PA. The aggravating role of the ubiquitin-proteasome system in neurodegeneration. FEBS Lett. 2005;579(3):5716.CrossRefGoogle ScholarPubMed
36. Shimura, H, Hattori, N, Kubo, S, Yoshikawa, M, Kitada, T, Matsumine, H, et al. Immumohistochemical and subcellular localization of parkin protein: absence of protein in autosomal recessive juvenile parkinsonism patients. Ann Neurol. 1999;45(5):66872.3.0.CO;2-Z>CrossRefGoogle Scholar
37. Schlossmacher, MG, Frosch, MP, Gai, WP, Medina, M, Sharma, N, Forno, L, et al. Parkin localizes to the Lewy bodies of Parkinson disease and dementia with Lewy bodies. Am J Pathol. 2002;160(5):165567.CrossRefGoogle ScholarPubMed
38. Rideout, HJ, Wang, Q, Park, DS, Stefanis, L. Cyclin-dependent kinase activity is required for apoptotic death but not inclusion formation in cortical neurons after proteasomal inhibition. J Neurosci. 2003;23(4):123745.Google Scholar
39. Dietrich, P, Rideout, HJ, Wang, Q, Stefanis, L. Lack of p53 delays apoptosis, but increases ubiquitinated inclusions, in proteasomal inhibitor-treated cultured cortical neurons. Mol Cell Neurosci. 2003;24(2):43041.CrossRefGoogle ScholarPubMed

Full text views

Full text views reflects PDF downloads, PDFs sent to Google Drive, Dropbox and Kindle and HTML full text views.

Total number of HTML views: 0
Total number of PDF views: 104 *
View data table for this chart

* Views captured on Cambridge Core between September 2016 - 1st March 2021. This data will be updated every 24 hours.

Access

Send article to Kindle

To send this article to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle. Find out more about sending to your Kindle.

Note you can select to send to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Proteasome Inhibitor Lactacystin Induces Cholinergic Degeneration
Available formats
×

Send article to Dropbox

To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Dropbox.

Proteasome Inhibitor Lactacystin Induces Cholinergic Degeneration
Available formats
×

Send article to Google Drive

To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Google Drive.

Proteasome Inhibitor Lactacystin Induces Cholinergic Degeneration
Available formats
×
×

Reply to: Submit a response


Your details


Conflicting interests

Do you have any conflicting interests? *